Studies have shown that growth outcomes of growth hormone therapy could be affected by multiple factors [8-10], among which, poor adherence is still a major problem in treating growth disorders for pediatric patients [11,12]. The gene discussed is GH1; the disease is hereditary endocrine growth disease.